Cite
HARVARD Citation
Le Gouill, S. et al. (2020). Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet. 7 (11), pp. e798-e807. [Online].